Our esteemed collaborators, Kalien M. from Stanford University School of Medicine, and Tim W. from Washington University School of Medicine in St. Louis presented leading-edge studies utilizing PMD-026. Their research underscores promising data supporting the efficacy of PMD-026 in treating myeloid cancers, including Acute Myeloid Leukemia (AML).